Titre : Survie sans rechute

Survie sans rechute : Questions médicales fréquentes

Termes MeSH sélectionnés :

Case-Control Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Survie sans rechute : Questions médicales les plus fréquentes", "headline": "Survie sans rechute : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Survie sans rechute : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-08", "dateModified": "2025-04-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Survie sans rechute" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Analyse de survie", "url": "https://questionsmedicales.fr/mesh/D016019", "about": { "@type": "MedicalCondition", "name": "Analyse de survie", "code": { "@type": "MedicalCode", "code": "D016019", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N06.850.520.830.998" } } }, "about": { "@type": "MedicalCondition", "name": "Survie sans rechute", "alternateName": "Disease-Free Survival", "code": { "@type": "MedicalCode", "code": "D018572", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Inkyu Kim", "url": "https://questionsmedicales.fr/author/Inkyu%20Kim", "affiliation": { "@type": "Organization", "name": "WWHEOR, Bristol Myers Squibb, Princeton, NJ, United States." } }, { "@type": "Person", "name": "Rachel Kerr", "url": "https://questionsmedicales.fr/author/Rachel%20Kerr", "affiliation": { "@type": "Organization", "name": "Adjuvant Colorectal Cancer Group, University of Oxford, Oxford, UK." } }, { "@type": "Person", "name": "Mukta Arora", "url": "https://questionsmedicales.fr/author/Mukta%20Arora", "affiliation": { "@type": "Organization", "name": "Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota." } }, { "@type": "Person", "name": "Sandhya Gokavarapu", "url": "https://questionsmedicales.fr/author/Sandhya%20Gokavarapu", "affiliation": { "@type": "Organization", "name": "Resident, Department of Oral and Maxillofacial- Head and Neck Oncology, Shanghai Stomatology key laboratory, Ninth People's Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease.", "datePublished": "2023-03-02", "url": "https://questionsmedicales.fr/article/36863401", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0042-1758448" } }, { "@type": "ScholarlyArticle", "name": "Axial Plane Rotation of the Talus in Progressive Collapsing Foot Deformity: A Weightbearing Computed Tomography Analysis.", "datePublished": "2023-03-02", "url": "https://questionsmedicales.fr/article/36864751", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10711007231154894" } }, { "@type": "ScholarlyArticle", "name": "Video Ocular Counter-Roll (vOCR): Otolith-Ocular Function and Compensatory Effect of the Neck Following Vestibular Loss.", "datePublished": "2023-03-02", "url": "https://questionsmedicales.fr/article/36861848", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ohn.304" } }, { "@type": "ScholarlyArticle", "name": "Fetal cell microchimerism and susceptibility to COVID-19 disease in women.", "datePublished": "2023-03-01", "url": "https://questionsmedicales.fr/article/36857020", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s15010-023-02006-x" } }, { "@type": "ScholarlyArticle", "name": "VNTR Polymorphism in the Intron 5 of SIRT3 and Susceptibility to Breast Cancer.", "datePublished": "2023-03-01", "url": "https://questionsmedicales.fr/article/36974538", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.31557/APJCP.2023.24.3.859" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Environnement et santé publique", "item": "https://questionsmedicales.fr/mesh/D004778" }, { "@type": "ListItem", "position": 3, "name": "Santé publique", "item": "https://questionsmedicales.fr/mesh/D011634" }, { "@type": "ListItem", "position": 4, "name": "Méthodes épidémiologiques", "item": "https://questionsmedicales.fr/mesh/D004812" }, { "@type": "ListItem", "position": 5, "name": "Statistiques comme sujet", "item": "https://questionsmedicales.fr/mesh/D013223" }, { "@type": "ListItem", "position": 6, "name": "Analyse de survie", "item": "https://questionsmedicales.fr/mesh/D016019" }, { "@type": "ListItem", "position": 7, "name": "Survie sans rechute", "item": "https://questionsmedicales.fr/mesh/D018572" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Survie sans rechute - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Survie sans rechute", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Survie sans rechute", "description": "Comment évaluer la survie sans rechute ?\nQuels tests sont utilisés pour le diagnostic ?\nQuand commence-t-on à mesurer la SSR ?\nQuels signes indiquent une rechute ?\nQuelle est l'importance du suivi régulier ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=999#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Survie sans rechute", "description": "Quels symptômes peuvent signaler une rechute ?\nLa fatigue est-elle un symptôme de rechute ?\nComment différencier les symptômes de rechute ?\nLes douleurs peuvent-elles indiquer une rechute ?\nLes changements d'appétit sont-ils significatifs ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=999#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Survie sans rechute", "description": "Comment prévenir les rechutes ?\nL'alimentation joue-t-elle un rôle dans la SSR ?\nL'exercice physique est-il bénéfique ?\nLes contrôles médicaux réguliers sont-ils importants ?\nLe soutien psychologique aide-t-il à la SSR ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=999#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Survie sans rechute", "description": "Quels traitements favorisent la SSR ?\nComment la chimiothérapie affecte-t-elle la SSR ?\nLa radiothérapie est-elle efficace pour la SSR ?\nQuels sont les effets secondaires des traitements ?\nComment le suivi post-traitement est-il organisé ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=999#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Survie sans rechute", "description": "Quelles complications peuvent survenir après traitement ?\nComment gérer les effets secondaires ?\nLes complications affectent-elles la SSR ?\nQuels sont les risques de récidive après traitement ?\nLes complications psychologiques sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=999#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Survie sans rechute", "description": "Quels facteurs augmentent le risque de rechute ?\nLe tabagisme influence-t-il la SSR ?\nL'hérédité joue-t-elle un rôle dans la rechute ?\nLe mode de vie influence-t-il la SSR ?\nL'âge est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=999#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la survie sans rechute ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La SSR est évaluée par des examens cliniques et des imageries régulières après traitement." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie comme le scanner ou l'IRM et des marqueurs tumoraux peuvent être utilisés." } }, { "@type": "Question", "name": "Quand commence-t-on à mesurer la SSR ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La SSR est généralement mesurée après la fin du traitement actif, souvent 3 à 6 mois après." } }, { "@type": "Question", "name": "Quels signes indiquent une rechute ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la douleur, la fatigue ou des anomalies dans les tests peuvent indiquer une rechute." } }, { "@type": "Question", "name": "Quelle est l'importance du suivi régulier ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi régulier permet de détecter précocement une rechute et d'adapter le traitement." } }, { "@type": "Question", "name": "Quels symptômes peuvent signaler une rechute ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur persistante, fatigue accrue, et perte de poids inexpliquée." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme de rechute ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une fatigue persistante peut être un signe de rechute et doit être évaluée." } }, { "@type": "Question", "name": "Comment différencier les symptômes de rechute ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il est essentiel de consulter un médecin pour évaluer les symptômes et leur origine." } }, { "@type": "Question", "name": "Les douleurs peuvent-elles indiquer une rechute ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs nouvelles ou persistantes doivent être examinées pour une possible rechute." } }, { "@type": "Question", "name": "Les changements d'appétit sont-ils significatifs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des changements d'appétit peuvent être un signe de rechute et nécessitent une attention médicale." } }, { "@type": "Question", "name": "Comment prévenir les rechutes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, des contrôles réguliers et le respect des traitements prescrits aident à prévenir les rechutes." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la SSR ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut renforcer le système immunitaire et aider à la SSR." } }, { "@type": "Question", "name": "L'exercice physique est-il bénéfique ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la santé globale et réduire le risque de rechute." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de détecter rapidement toute rechute potentielle." } }, { "@type": "Question", "name": "Le soutien psychologique aide-t-il à la SSR ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le soutien psychologique peut améliorer la qualité de vie et aider à faire face au stress." } }, { "@type": "Question", "name": "Quels traitements favorisent la SSR ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements comme la chirurgie, la chimiothérapie et la radiothérapie visent à prolonger la SSR." } }, { "@type": "Question", "name": "Comment la chimiothérapie affecte-t-elle la SSR ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie peut réduire la taille des tumeurs et améliorer les chances de SSR." } }, { "@type": "Question", "name": "La radiothérapie est-elle efficace pour la SSR ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut aider à éliminer les cellules cancéreuses et améliorer la SSR." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure nausées, fatigue, et immunosuppression, affectant la qualité de vie." } }, { "@type": "Question", "name": "Comment le suivi post-traitement est-il organisé ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi post-traitement inclut des consultations régulières et des examens pour surveiller la SSR." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après traitement ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme l'infection, la fatigue chronique ou des effets secondaires des traitements peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des effets secondaires inclut des soins symptomatiques et un suivi médical régulier." } }, { "@type": "Question", "name": "Les complications affectent-elles la SSR ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent influencer négativement la survie sans rechute." } }, { "@type": "Question", "name": "Quels sont les risques de récidive après traitement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les risques de récidive varient selon le type de cancer et le traitement reçu, nécessitant un suivi." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications psychologiques comme l'anxiété et la dépression peuvent survenir après le traitement." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de rechute ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme le type de cancer, le stade au diagnostic et l'âge peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la SSR ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque connu qui peut affecter la survie sans rechute." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans la rechute ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de rechute." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il la SSR ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire le risque de rechute et améliorer la SSR." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé peut être associé à un risque accru de rechute après traitement." } } ] } ] }

Sources (10000 au total)

Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease.

Cognitive deficit in Parkinson disease (PD) is an important cause of functional disability in these patients and early detection, with sensitive instruments, can contribute to longitudinal monitoring.... To investigate the diagnostic accuracy, sensitivity, and specificity of the Addenbrooke's Cognitive Examination-III in patients with PD, using the comprehensive neuropsychological battery as reference... Cross-sectional, observational, case-control study.... rehabilitation service. A total of 150 patients and 60 healthy controls matched for age, sex, and education. For level I assessment, Addenbrooke Cognitive Examination (ACE-III) was used. Level II asse... The clinical group was divided into 3 subgroups: normal cognition in Parkinson's disease (NC-PD-16%), mild cognitive impairment due to Parkinson's disease (MCI-PD-69.33%), and dementia due to Parkinso... ACE-III is a useful battery for assessing the cognitive domains and to differentiate individuals with MCI-PD and D-PD from healthy controls. Future research, in a community setting, is necessary to pr...

Axial Plane Rotation of the Talus in Progressive Collapsing Foot Deformity: A Weightbearing Computed Tomography Analysis.

Progressive collapsing foot deformity (PCFD) is recognized as a 3-dimensional deformity centered around the talus. Previous studies have described some features of talar motion in the ankle mortise in... Multiplanar reconstructed WBCT images of 79 patients with PCFD and 35 control patients (39 scans) were retrospectively analyzed. The PCFD group was divided into 2 subgroups depending on preoperative t... The talus was significantly more internally rotated with respect to the ankle TM axis and the lateral malleolus in PCFD patients compared to controls, and in the severe abduction group compared with t... Our findings suggest that talar malrotation in the axial plane should be considered an underlying feature of abduction deformity in PCFD. The malrotation occurs in both the talonavicular and ankle joi... Level III, case-control study....

Video Ocular Counter-Roll (vOCR): Otolith-Ocular Function and Compensatory Effect of the Neck Following Vestibular Loss.

Assessment of recovery following vestibular loss has been limited by the lack of bedside measures in clinical settings. Here, we used the video ocular counter-roll (vOCR) test to study otolith-ocular ... Case-control study.... Tertiary care center.... Fifty-six subjects were recruited including patients with acute (9 ± 2 days [mean ± standard error of mean]), subacute (61 ± 11 days), and chronic (1009 ± 266 days) unilateral loss of vestibular funct... The vOCR responses evolved at different stages following vestibular loss with improvement of the gains in the chronic stage. The deficit was more pronounced when the whole body was tilted (acute: 0.08... The vOCR test can be valuable as a clinical marker to measure vestibular recovery and compensatory effect of neck proprioception in patients at different stages following loss of vestibular function....

Fetal cell microchimerism and susceptibility to COVID-19 disease in women.

The clinical outcome of COVID-19 disease is worse in males, and the reasons of this gender disparity are currently unclear, though evidences point to a combination of biological and gender-specific fa... One hundred twenty-three women with a previous male pregnancy, comprising 63 COVID-19 cases and 60 healthy controls were enrolled. The presence of blood male DNA was assessed by the amplification of t... The prevalence of male DNA of presumed fetal origin was significantly higher in healthy controls than in COVID-19 cases (70 vs 44.4%, P = 0.0044; OR 0.3429, 95% CI 0.1631-0.7207, P = 0.0047). Among wo... This is the first case-control study reporting the prevalence of FCM in COVID-19 and healthy women. Overall, our data seem to suggest a role for FCM in the protection towards the SARS-CoV-2 infection ...

VNTR Polymorphism in the Intron 5 of SIRT3 and Susceptibility to Breast Cancer.

Breast cancer recurrence and metastasis are associated with alterations in the cellular stress responses that influence tumour signalling. Sirtuin3 (SIRT3), a mitochondrial deacetylase is the regulato... The current case-control study was conducted in Hyderabad, India. A total of 200 primary female breast cancer cases were recruited, irrespective of age and clinical subtype. However, secondary or recu... The VNTR polymorphism in the intron 5 region of SIRT3 gene could serve as a molecular marker for detection of breast cancer onset. Further studies are warranted to study the prognostic and therapeutic...

Attenuated cognitive functioning decades after preeclampsia.

Preeclampsia, a hypertensive pregnancy disorder, is a leading cause of maternal and fetal morbidity and mortality, with remote cardio- and cerebrovascular implications. After preeclampsia, women may r... This study aimed to determine the impact of preeclampsia on perceived maternal cognitive functioning decades after pregnancy.... This study is part of a cross-sectional case-control study named Queen of Hearts (ClinicalTrials.gov Identifier: NCT02347540), a collaboration study of 5 tertiary referral centers within the Netherlan... This study included 1036 women with a history of preeclampsia and 527 women with normotensive pregnancies. Regarding overall executive function, 23.2% (95% confidence interval, 19.0-28.1) of women exp... After preeclampsia, women were 9 times more likely to experience clinical attenuation of higher-order cognitive functions as opposed to after normotensive pregnancy. Despite overall steady improvement...